Lab-on-Chip-Based Platform for Fast Molecular Diagnosis of Multidrug-Resistant Tuberculosis

Author:

Cabibbe Andrea M.1,Miotto Paolo1,Moure Raquel2,Alcaide Fernando2,Feuerriegel Silke3,Pozzi Gianni4,Nikolayevskyy Vladislav56,Drobniewski Francis56,Niemann Stefan3,Reither Klaus78,Cirillo Daniela M.1

Affiliation:

1. Emerging Bacterial Pathogens Unit, Division of Immunology, Transplantation and Infectious Diseases, IRCCS San Raffaele Scientific Institute, Milan, Italy

2. Servei de Microbiologia, Hospital Universitari de Bellvitge-IDIBELL, Universitat de Barcelona, Barcelona, Spain

3. Molecular Mycobacteriology, Research Center Borstel, Borstel, Germany

4. Laboratory of Molecular Microbiology and Biotechnology, Department of Medical Biotechnologies, University of Siena, Siena, Italy

5. Clinical TB and HIV Group, Blizard Institute, Queen Mary University of London, London, United Kingdom

6. Department of Infectious Diseases and Immunity, Imperial College London, London, United Kingdom

7. Swiss Tropical and Public Health Institute, Basel, Switzerland

8. Ifakara Health Institute, Bagamoyo, United Republic of Tanzania

Abstract

ABSTRACT We evaluated the performance of the molecular lab-on-chip-based VerePLEX Biosystem for detection of multidrug-resistant tuberculosis (MDR-TB), obtaining a diagnostic accuracy of more than 97.8% compared to sequencing and MTBDR plus assay for Mycobacterium tuberculosis complex and rifampin and isoniazid resistance detection on clinical isolates and smear-positive specimens. The speed, user-friendly interface, and versatility make it suitable for routine laboratory use.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Reference26 articles.

1. World Health Organization. 2014. Global tuberculosis report 2014. World Health Organization, Geneva, Switzerland.

2. European Centre for Disease Prevention and Control/WHO Regional Office for Europe. 2014. Tuberculosis surveillance and monitoring in Europe 2014. European Centre for Disease Prevention and Control, Stockholm, Sweden.

3. Diagnosis of tuberculosis and drug resistance: what can new tools bring us? [State of the art series. New tools. Number 1 in the series]

4. Advances in tuberculosis diagnostics: the Xpert MTB/RIF assay and future prospects for a point-of-care test

5. Evaluation of Two Line Probe Assays for Rapid Detection of Mycobacterium tuberculosis, Tuberculosis (TB) Drug Resistance, and Non-TB Mycobacteria in HIV-Infected Individuals with Suspected TB

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3